KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares RepurchasedShort-Term Debt repayments
Ratios

Emergent BioSolutions (EBS) Receivables - Net (2016 - 2025)

Emergent BioSolutions (EBS) has 16 years of Receivables - Net data on record, last reported at $66.8 million in Q4 2025.

  • For Q4 2025, Receivables - Net fell 56.76% year-over-year to $66.8 million; the TTM value through Dec 2025 reached $66.8 million, down 56.76%, while the annual FY2025 figure was $66.8 million, 50.66% down from the prior year.
  • Receivables - Net reached $66.8 million in Q4 2025 per EBS's latest filing, down from $149.5 million in the prior quarter.
  • Across five years, Receivables - Net topped out at $290.1 million in Q2 2023 and bottomed at $58.2 million in Q2 2025.
  • Average Receivables - Net over 5 years is $170.9 million, with a median of $157.5 million recorded in 2022.
  • Peak YoY movement for Receivables - Net: soared 141.95% in 2023, then crashed 58.39% in 2024.
  • A 5-year view of Receivables - Net shows it stood at $278.9 million in 2021, then tumbled by 42.92% to $159.2 million in 2022, then decreased by 10.93% to $141.8 million in 2023, then increased by 8.96% to $154.5 million in 2024, then tumbled by 56.76% to $66.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables - Net were $66.8 million in Q4 2025, $149.5 million in Q3 2025, and $58.2 million in Q2 2025.